中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
Evaluation and Analysis of Drug-Use in Hospitals of China
2015年
9期
1142-1144
,共3页
郭蕊%焦雪峰%陈爽%罗琳
郭蕊%焦雪峰%陳爽%囉琳
곽예%초설봉%진상%라림
阿莫西林/克拉维酸钾%耐多药肺结核%痰菌阴转率%病灶吸收%空洞闭合
阿莫西林/剋拉維痠鉀%耐多藥肺結覈%痰菌陰轉率%病竈吸收%空洞閉閤
아막서림/극랍유산갑%내다약폐결핵%담균음전솔%병조흡수%공동폐합
Amoxycillin/clavulanate potassium%Multidrug resistance tuberculosis%Sputum negative conversion%Focal absorption%Cavity closure
目的：探讨阿莫西林／克拉维酸钾联合常规抗结核药治疗耐多药肺结核（ multidrug resistance tuberculosis ，MDR-TB）的临床疗效和不良反应。方法：将205例MDR-TB患者按随机数字表法分为观察组103例和对照组102例。对照组患者给予吡嗪酰胺、乙胺丁醇、对氨基水杨酸异烟肼、利福喷丁和左氧氟沙星，观察组患者在对照组治疗的基础上加用阿莫西林／克拉维酸钾，2组疗程均为12个月。观察患者的痰菌阴转、病灶吸收、空洞闭合和不良反应发生情况。结果：治疗3个月后，2组患者痰菌阴转率的差异无统计学意义（P＞0.05）；治疗6、9、12个月后，观察组患者痰菌阴转率分别为68.93％（71／103）、74.76％（77／103）和81.55％（84／103），均明显高于对照组的50.98％（52／102）、55.88％（57／102）和60.78％（62／102），差异有统计学意义（P＜0.05）；疗程结束时观察组与对照组患者的病灶吸收总有效率分别为88.35％（91／103）和66.67％（68／102），空洞闭合总有效率分别为84.47％（87／103）和64.71％（66／102），观察组均明显优于对照组，差异均有统计学意义（P＜0.05）。结论：阿莫西林／克拉维酸钾联合常规抗结核药治疗MDR-TB安全、有效，但短期疗效优势不明显。
目的：探討阿莫西林／剋拉維痠鉀聯閤常規抗結覈藥治療耐多藥肺結覈（ multidrug resistance tuberculosis ，MDR-TB）的臨床療效和不良反應。方法：將205例MDR-TB患者按隨機數字錶法分為觀察組103例和對照組102例。對照組患者給予吡嗪酰胺、乙胺丁醇、對氨基水楊痠異煙肼、利福噴丁和左氧氟沙星，觀察組患者在對照組治療的基礎上加用阿莫西林／剋拉維痠鉀，2組療程均為12箇月。觀察患者的痰菌陰轉、病竈吸收、空洞閉閤和不良反應髮生情況。結果：治療3箇月後，2組患者痰菌陰轉率的差異無統計學意義（P＞0.05）；治療6、9、12箇月後，觀察組患者痰菌陰轉率分彆為68.93％（71／103）、74.76％（77／103）和81.55％（84／103），均明顯高于對照組的50.98％（52／102）、55.88％（57／102）和60.78％（62／102），差異有統計學意義（P＜0.05）；療程結束時觀察組與對照組患者的病竈吸收總有效率分彆為88.35％（91／103）和66.67％（68／102），空洞閉閤總有效率分彆為84.47％（87／103）和64.71％（66／102），觀察組均明顯優于對照組，差異均有統計學意義（P＜0.05）。結論：阿莫西林／剋拉維痠鉀聯閤常規抗結覈藥治療MDR-TB安全、有效，但短期療效優勢不明顯。
목적：탐토아막서림／극랍유산갑연합상규항결핵약치료내다약폐결핵（ multidrug resistance tuberculosis ，MDR-TB）적림상료효화불량반응。방법：장205례MDR-TB환자안수궤수자표법분위관찰조103례화대조조102례。대조조환자급여필진선알、을알정순、대안기수양산이연정、리복분정화좌양불사성，관찰조환자재대조조치료적기출상가용아막서림／극랍유산갑，2조료정균위12개월。관찰환자적담균음전、병조흡수、공동폐합화불량반응발생정황。결과：치료3개월후，2조환자담균음전솔적차이무통계학의의（P＞0.05）；치료6、9、12개월후，관찰조환자담균음전솔분별위68.93％（71／103）、74.76％（77／103）화81.55％（84／103），균명현고우대조조적50.98％（52／102）、55.88％（57／102）화60.78％（62／102），차이유통계학의의（P＜0.05）；료정결속시관찰조여대조조환자적병조흡수총유효솔분별위88.35％（91／103）화66.67％（68／102），공동폐합총유효솔분별위84.47％（87／103）화64.71％（66／102），관찰조균명현우우대조조，차이균유통계학의의（P＜0.05）。결론：아막서림／극랍유산갑연합상규항결핵약치료MDR-TB안전、유효，단단기료효우세불명현。
OBJECTIVE:To probe into the clinical efficacy and adverse drug reaction of amoxycillin /clavulanate potassium combined with conventional anti-TB drugs in treatment of multidrug resistance tuberculosis ( MDR-TB ) . METHODS:205 MDR-TB patients were divided into treatment group (103 patients) and control group (102 patients) by random number table .The control group was given amoxycillin , ethambutol , isoniazid aminosalicylate , rifapentine and levofloxacin , the observation group received amoxycillin/clavulanate potassiumthe based on the same treatment regimen of the control group .The treatment course of 2 groups was 12 months.The changes of sputum negative conversion, focal absorption, cavity, the improved clinical symptoms and negative ADR consequences were closely observed in two groups .RESULTS:After the treatment of 3 months, there was no statistically significant difference of the sputum negative conversion rate in 2 groups ( P>0.05 ) .In the treatment group , the sputum negative rate at the sixth, ninth and twelfth month were respectively 68.93%(71/103), 74.76%(77/103) and 81.55%(84/103), which was significantly higher than that in the control group 50.98%( 52/102 )、55.88%( 57/102 ) and 60.78%(62/102) respectively, with statistically significant difference ( P >0.05).At the end of the treatment, the focal absorption rate of treatment group and control group was respectively 88.35%(91/103) and 66.67%(68/102), the cavity closure rate of treatment group and control group were respectively 84.47%(87/103) and 64.71%(66/102);the above-mentioned indexes in the treatment group were all significantly better than that in the control group , with significant difference ( P<0.05 ) .CONCLUSIONS:It is safe and effective to use amoxycillin/clavulanate potassium in the treatment of MDR-TB, but still have few significant advantages in the short-term efficacy.
